Lead Product(s) : Recombinant Coagulation Factor Ix
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Medexus reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B.
Product Name : Ixinity
Product Type : Protein
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Recombinant Coagulation Factor Ix
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable